, , .
, , , , , , , , , . 1% : , , , , , , , , , , , , , , , , -, , , , , , , ( ), , , ( ), , . (<1%)
33 Krause P. R., Klinman D. M. Efficacy, immunogenicity, safety, and use of live attenuated
chickenpox vaccine. J. Pediatr. 1995(4); 127:518-525.
34
,
.
100 .
,
( . . . ., 1999, . 116). 100
, ,
. ,
, ,
-.
(<0.1%). : , , , -, , , , , , -, , , -, , , .
12 . .
-ϻ, .
: 99% 35. . , , , 100%, , . , ; . , , , , . (-, ), , , , ... 44%. , , , , , , . , -
|
|
35 : 85% . (87% ) Vazquez M. etal. The effectiveness of the varicella vaccine in clinical practice. N. Engl. J. Med. Mar 29, 2001; 344 (13):955-60. 1997 . 2000 . - (, ). 274 , , 56 (20,43%) , , , .
. , , , , (, , ). , 2001 ., , 55%. 36 . , : ; , , .
, , , , 4-5 37.
, , . , 24 , , , 38. , , 39 39. -
36 ,
47 (Boodman S. G. An Imperfect Vaccine:
Chickenpox Cases Stir Call for Booster. Washington Post December 24, 2002; p. HE06). Bo
() 44
42.
,
(Chickenpox outbreak investigated at Gale-Ettrick-Trempealeau. Associated Press
20.01.2006). .
():
( ),
. ,
(Clower . Chicken pox outbreak. Troy Messenger February 27, 2006).
|
|
37 ., , Nolan . et al. Reactogenicity and immunogenicity of a live attenuated
tetravalent measles-mumps-rubella-varicella (MMRV) vaccine. Vaccine Dec 2002; 21:281-9
ArbeterA. M. et al. The combination measles, mumps, rubella and varicella vaccine in healthy
children. Dev. . Stand. 1986; 65:89-93.
38 Salzman M. B. et al. Transmission of varicella-vaccine virus from a healthy 12-month-old
child to his pregnant mother. J. Pediatr. 1997(1); 131:151-154.
39 Huang W. et al. Transmission of varicella to a gravida via close contacts immunized with
varicella-zoster vaccine. A case report. J. Reprod. Med. Oct 1999; 44(10):905-7.
( 3,4% , 3,8% 40), , , .
, , , , . , , . ?
,
,
, .
, ,
.
.
,
.
, ,
.
, ,
, .
,
, . -
, ,
. ,
,
,
.
40 Leung . ., . P. The truth about chickenpox. Can. J. Diagn. 1999; 16(12):79-87.
- 15-20 , , , . , , , . , , , , - . ; , - . 30 ( 50). , , ( , , , ), , , , , . , , , 10-30% , , 1.
|
|
, . , , - -
1 , , 70% . , ( . . ) (1:1 1:50 1:100 ) ( . . . XX . , 2003, . 58).
, . : . , 2 3 . (90%) 3-4 . . 10% 3-4 , 4. - , , : . 1-3 , - . , ( ). , . . 5. , , , , , , - , . , . . - . , .
, , . , (67%), 70% 49 6.
|
|
2 , ; . fulminare . . .
3 . ., . . . . ., 2001,
. 198.
4 . . , 2000, . 136.
5 . . . . , 2003, . 72.
6 Hadler S. G. Global impact of hepatitis A virus infection changing patterns // Hollinger F. .,
Lemon S. M., Margolis H. (eds.) Viral hepatitis and liver disease. Baltimore, 1991, pp. 14-20.
, (, ). , . , , . , TIM-1, . , , , 7.
, , 8 , , . . : - 90- , : 1998 . 34,0 100 . ... - : . , . , , , ; ( ) . , 9. , 100 . 1992-1996 . 106,9 , 1997-2001 . 50. , -
7 Mclntire J. J. et al. Immunology: hepatitis A virus link to atopic disease Nature Oct 2003-
425:576.
8 ,
90%
. .
9 . . ... . 57.
46,68 2002 . 28,41 2003 . : 1983 . 9,2, 1989 . 14,6 100 . 10.
, , : , , , . , , ? , , , , , , , 11. . ( ? , ?) -: - , . , (?! . .), , , , 12.
|
|
10 Shapiro . N. et al. Epidemiology of hepatitis A in the United States // Hollinger F. B. Viral... pp. 71-76.
11 . , . -- 29% , 9% . - ( . . : ! , 2001, 1).
12 . . ... . 61. : , . - ( . . -... . 198). , 2001 ., . , : , , - , . , -
, , , . (, ?), ... , , . , , . , , , , , ( , ) . , , . , , , , , .
, , , : , : , ( . . .). , 1997-1999 . (16,3-29,5 100 .) 207,4-316,6 1992-1996 . 13. , .
( . . . , 2003, 7, . 6-10). , , , - . , , , , .
13 . . . // , (, ), . . -, 29-31 2000 .
1995 . ( ), (- ). . , -- ( , ), - , . , , . , , , 14. , .
: , . 15.
, : 1 10% , , , ( 37,5); 1% , , , , , , , , , , , , , , , . 14% 9% . , , , , , , , , , , , , , , -, ; , , - 16. , , , .
14 Havrix (Hepatits A Vaccine, Inactivated). Prescribing information.
115 .
116 .
, , , .
, , - , , . , , , , .
84%17. , .
, , , . , DPT (). , , . , , , , .
, , .
12- . . 6-12 . 0, 1, 6 . 5
17 .
18. : ... 5 19. 5 - ... 20 : 20 ... ( , ), - . , , 20 20. , 40, 60 , . , , , , , 21. , . . , . . ( ) .